Home > Journals > Minerva Biotechnology and Biomolecular Research > Past Issues > Minerva Biotecnnology and Biomolecular Research 2021 March;33(1) > Minerva Biotechnology and Biomolecular Research 2021 March;33(1):29-35

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   Freefree

Minerva Biotechnology and Biomolecular Research 2021 March;33(1):29-35

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

In silico identification of linear B-cell epitope in Coronavirus 2019 (SARS-CoV-2) surface glycoprotein: a prospective towards peptide vaccine

Pushpendra SINGH 1, Manish K. TRIPATHI 2, Rahul SHRIVASTAVA 3

1 ICAR- National Institute of High Security Animal Diseases, Bhopal, India; 2 Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology, Banaras Hindu University, Varanasi, India; 3 Department of Biological Science and Engineering, Maulana Azad National Institute of Technology, Bhopal, India


PDF


BACKGROUND: The 2020 Coronavirus pandemic continuing spread of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). At the moment, there is no specific antiviral treatment or monoclonal antibodies or vaccines available for COVID-19. SARS-CoV-2 is positive-stranded RNA viruses with a crown-like appearance due to the occurrence of spike (surface) glycoproteins on the envelope. In the present study, the computational method used to predict the significant linear B cell epitopes of SARS-CoV-2 surface glycoprotein.
METHODS: FASTA sequence of SARS-CoV-2 surface glycoprotein was retrieved from the NCBI database, and further its primary and secondary structure was analyzed for its physical and chemicals properties. IEDB server was used to predict the B-cell epitopes.
RESULTS: ABCprep server and IEDB server prediction results for B-cell epitopes showed 16 and 21 linear epitope sequences respectively in the surface glycoprotein of SARS-CoV-2.
CONCLUSIONS: Obtained results conclude that predicted B-cell Epitopes may serve as an immunogen for eliciting monoclonal antibodies which can be used as a potential candidate for the treatment or diagnostic purpose for COVID-19.


KEY WORDS: Coronavirus; COVID-19; Severe acute respiratory syndrome coronavirus 2; Epitopes, B-lymphocyte; Pandemics

top of page